Sue Marshall blogs about diabetes for Desang

Novo Nordisk’s Type 2 Drug Victoza Hits Minor Snag | Diabetes News Hound | December 30, 2009

Danish drugmaker Novo Nordisk said the U.S. Food and drug Administration has delayed providing feedback on its once-a-day Type 2 diabetes drug Victoza, according to a recent article from Reuters.

Analysts had been expecting feedback on the drug, known as liraglutide in Europe, by the end of the year. The drug pushes the body to release extra insulin when blood sugar levels run high. It has been approved in Europe, but regulatory approval has been delayed in the U.S., a cause for concern to some. A Novo spokesman said the company is convinced there is no need for alarm and that the approval process is simply taking longer than normal. The company expects formal feedback within weeks. If it does not get it, it will provide an update on the drug on Feb. 2, 2010, along with its financial results.

Victoza expects to compete with Byetta from Eli Lilly and Amylin Pharmaceuticals. GlaxoSmithKline and Roche Holding AG are also developing drugs in the same class.

via Novo Nordisk’s Type 2 Drug Victoza Hits Minor Snag | Diabetes News Hound.


Leave a Comment »

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

    Search Sue Marshall’s blog

    Desang Diabetes Directory

    See our directory of diabetes management kit -- blood test machines, insulin delivery devices, finger-prickers.

    Sue Marshall picture

    Sue Marshall

%d bloggers like this: